Stroma-tumor crosstalk converges with oncogenic KRAS signaling to drive an NFκB-mediated immune evasion program (AACRPanCa 2026) - Oct 15, 2026 - Abstract #B101; "We find that a selective KRASG12D inhibitor (MRTX-1133) and a multi-selective RAS(ON) inhibitor (RMC-6326) could sensitize TIF-treated tumor cells to T cell killing through both FAS-dependent and FAS-independent mechanisms...In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026; 86(18_Suppl_2):Abstract nr B101."
IO biomarker • Stroma • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • FASLG • KRAS
|
|
Yuwenbin Li; Morgan Truitt; Daniel Cao; Jonathan Zhu; Yang Dai; Mariel Burquez-Escobedo; Gaoyang Liang; Michael Downes; Annette Atkins; Ruth Yu; Ronald Evans
|